Your browser doesn't support javascript.
loading
Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma.
Rauf, M Shahzad; Khan, Z A; Zahir, M N; Al-Sweedan, Suleimman; Al-Kofide, Amani; Alharthy, Hannan; Almugbel, Fahad A; Osmani, Asif; Elhassan, Tusneem Ahmed M; Khafaga, Yasser; Maghfoor, Irfan; Akhtar, Saad.
Afiliação
  • Rauf MS; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
  • Khan ZA; Nuclear Medicine/Radiology Department.
  • Zahir MN; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
  • Al-Sweedan S; Pediatric Hematology/Oncology Department.
  • Al-Kofide A; Pediatric Hematology/Oncology Department.
  • Alharthy H; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
  • Almugbel FA; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
  • Osmani A; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
  • Elhassan TAM; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
  • Khafaga Y; Radiation Oncology Department, King Abdullah Centre for Oncology and Liver Diseases, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
  • Maghfoor I; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
  • Akhtar S; Medical Oncology Department, King Abdullah Centre for Oncology and Liver Diseases.
Nucl Med Commun ; 42(8): 899-906, 2021 Aug 01.
Article em En | MEDLINE | ID: mdl-33852535
BACKGROUND: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma. Data are limited regarding 18F-labelled fluoro-2-deoxyglucose (FDG)-PET use in NLPHL. We are reporting our experience with FDG-PET utility in staging and response assessment NLPHL patients. METHODS: We retrospectively studied a population of all newly diagnosed or relapsed/refractory patients who underwent both pre-treatment contrast-enhanced computed tomography (CeCT) and an FDG-PET and also at the end of planned treatment. RESULTS: We identified 68 patients found to have in total 312 scans, 78 paired pre-therapeutic and post-treatment CeCT and FDG-PET scans. Among them, 55 were male, with a median follow-up was 48 months. Median SUV-max was 8.3 (2.0-21.0). FDG-PET and CeCT were concordant in 80% (62/78) of staging scans. In 20% (16/78) of patients in whom a discordance was observed, FDG-PET resulted in upstaging in 13 scans and downstaging in 3 scans. The sensitivity of CeCT was 92% for nodal staging and 42% for extralymphatic staging when compared to FDG-PET. The specificity of CeCT was 98% as compared to FDG-PET. For response assessment, there was poor agreement between the CeCT and FDG-PET in assigning complete remission of disease scores as FDG-PET was able to identify the absence of disease despite the presence of a radiologically evident residual mass on CeCT. The sensitivity for CeCT compared to FDG-PET was 100% while the specificity was 43% for detection of post-treatment response. CONCLUSION: For NLPHL, pre-therapeutic FDG-PET scan is better than CeCT staging. FDG-PET has much better specificity for response assessment than CeCT.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Fluordesoxiglucose F18 / Tomografia por Emissão de Pósitrons Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Fluordesoxiglucose F18 / Tomografia por Emissão de Pósitrons Idioma: En Ano de publicação: 2021 Tipo de documento: Article